Lonza: Contract to generate research grade iPSCs by the National Institutes of Health Center for Regenerative Medicine
The National Institutes of Health Center for Regenerative Medicine (NIH) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) for research purposes.
By definition, iPSCs have the ability to indefinitely self-renew and become any cell type in the body. Because of these attributes, iPSCs have become an important scientific tool and are spurring advancements in basic research, disease modeling, drug development, and regenerative medicine.
The contract awarded to Lonza is deemed an Indefinite Delivery/Indefinite Quantity (IDIQ) award which is a type of United States Government contract that provides an indefinite quantity of services for a fixed amount of time. For IDIQs, although nothing is guaranteed, minimum and maximum quantity limits are specified in the basic contract as either number of units (for supplies) or as dollar values (for services). The Lonza contract is a three year agreement with a value up to $6.9 million dollars.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.